Legend Study: Eg-70 In Nmibc Patients Bcg-Unresponsive And High-Risk Nmibc Incompletely Treated With Bcg Or Bcg-Naïve
Posted Date: Apr 26, 2024
- Investigator: Mohamed Kamel
- Specialties:
- Type of Study: Drug
This study will evaluate the safety and efficacy of intravesical administration of EG-70 in the bladder and its effect on bladder tumors in patients with NMIBC. This study study consists of two phases; a Phase 1 dose-escalation to establish safety and recommended the phase 2 dose, followed by a Phase 2 study to establish how effective the treatment is. The Study will include patients with NMIBC with Cis for whom BCG therapy is unresponsive and patients with NMIBC with Cis who are BCG-naïve or inadequately treated.
Criteria:
Null
Keywords:
Bladder Cancer
For More Information:
Meagan Thomas
NULL
cancer@uchealth.com